M. C. Keefer

1.3k total citations
15 papers, 1.1k citations indexed

About

M. C. Keefer is a scholar working on Virology, Epidemiology and Molecular Biology. According to data from OpenAlex, M. C. Keefer has authored 15 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Virology, 7 papers in Epidemiology and 5 papers in Molecular Biology. Recurrent topics in M. C. Keefer's work include HIV Research and Treatment (13 papers), vaccines and immunoinformatics approaches (5 papers) and HIV/AIDS Research and Interventions (4 papers). M. C. Keefer is often cited by papers focused on HIV Research and Treatment (13 papers), vaccines and immunoinformatics approaches (5 papers) and HIV/AIDS Research and Interventions (4 papers). M. C. Keefer collaborates with scholars based in United States and South Africa. M. C. Keefer's co-authors include Raphael Dolin, Robert B. Belshe, Geoffrey J. Gorse, David H. Schwartz, M. Juliana McElrath, M L Clements, Barney S. Graham, Lawrence Corey, Donald S. Burke and John R. Mascola and has published in prestigious journals such as Annals of Internal Medicine, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

M. C. Keefer

15 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. C. Keefer United States 13 843 465 342 316 310 15 1.1k
Mary Clare Walker United States 11 646 0.8× 367 0.8× 257 0.8× 229 0.7× 357 1.2× 25 911
Paul T. Edlefsen United States 13 679 0.8× 306 0.7× 213 0.6× 220 0.7× 506 1.6× 31 991
Nina D. Russell United States 14 349 0.4× 280 0.6× 212 0.6× 184 0.6× 170 0.5× 23 605
Dennis Ellenberger United States 19 737 0.9× 299 0.6× 174 0.5× 269 0.9× 609 2.0× 40 1.0k
Mary N. Phillips United States 7 1.3k 1.6× 835 1.8× 181 0.5× 325 1.0× 699 2.3× 7 1.5k
Supachai Rerks‐Ngarm Thailand 15 509 0.6× 303 0.7× 195 0.6× 245 0.8× 291 0.9× 43 809
Christine Hogan United States 13 1.3k 1.6× 627 1.3× 146 0.4× 347 1.1× 854 2.8× 16 1.6k
William M. Hurni United States 13 219 0.3× 238 0.5× 212 0.6× 392 1.2× 184 0.6× 25 804
R R Redfield United States 8 424 0.5× 168 0.4× 140 0.4× 293 0.9× 328 1.1× 8 746
M J McElrath United States 12 528 0.6× 381 0.8× 132 0.4× 375 1.2× 291 0.9× 13 960

Countries citing papers authored by M. C. Keefer

Since Specialization
Citations

This map shows the geographic impact of M. C. Keefer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. C. Keefer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. C. Keefer more than expected).

Fields of papers citing papers by M. C. Keefer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. C. Keefer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. C. Keefer. The network helps show where M. C. Keefer may publish in the future.

Co-authorship network of co-authors of M. C. Keefer

This figure shows the co-authorship network connecting the top 25 collaborators of M. C. Keefer. A scholar is included among the top collaborators of M. C. Keefer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. C. Keefer. M. C. Keefer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Malahleha, Mookho, et al.. (2022). Exploring a community’s understanding of HIV vaccine‑induced seropositivity in a South African research setting. South African Medical Journal. 113(1). 36–41. 2 indexed citations
2.
Gilbert, Peter B., Ya Lin Chiu, Mary Allen, et al.. (2003). Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine. 21(21-22). 2933–2947. 55 indexed citations
3.
Evans, Thomas G., et al.. (1998). Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers. Clinical & Experimental Immunology. 111(2). 243–250. 12 indexed citations
4.
Coombs, Robert W., M. Juliana McElrath, M. C. Keefer, et al.. (1997). Longitudinal Analysis of Quantitative Virologic Measures in Human Immunodeficiency Virus-Infected Subjects with >=400 CD4 Lymphocytes: Implications for Applying Measurements to Individual Patients. The Journal of Infectious Diseases. 175(2). 247–254. 78 indexed citations
5.
Keefer, M. C., Mark Wolff, Geoffrey J. Gorse, et al.. (1997). Safety Profile of Phase I and II Preventive HIV Type 1 Envelope Vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Research and Human Retroviruses. 13(14). 1163–1177. 66 indexed citations
6.
Mascola, John R., S W Snyder, O. S. Weislow, et al.. (1996). Immunization with Envelope Subunit Vaccine Products Elicits Neutralizing Antibodies against Laboratory-Adapted but Not Primary Isolates of Human Immunodeficiency Virus Type 1. The Journal of Infectious Diseases. 173(2). 340–348. 354 indexed citations
7.
Gorse, Geoffrey J., M. C. Keefer, Robert B. Belshe, et al.. (1996). A Dose-Ranging Study of a Prototype Synthetic HIV-1MN V3 Branched Peptide Vaccine. The Journal of Infectious Diseases. 173(2). 330–339. 48 indexed citations
8.
Graham, Barney S., Geoffrey J. Gorse, David H. Schwartz, et al.. (1994). Determinants Of Antibody Response After Recombinant Gp160 Boosting In Vaccinia-Naive Volunteers Primed With Gp160-Recombinant Vaccinia Virus. The Journal of Infectious Diseases. 170(4). 782–786. 29 indexed citations
9.
Belshe, Robert B., M L Clements, M. C. Keefer, et al.. (1994). Interpreting HIV Serodiagnostic Test Results in the 1990s: Social Risks of HIV Vaccine Studies in Uninfected Volunteers. Annals of Internal Medicine. 121(8). 584–589. 47 indexed citations
10.
Daher, N, M. C. Keefer, Richard C. Reichman, Raphael Dolin, & Norbert J. Roberts. (1993). Persisting Human Immunodeficiency Virus Type 1 gp160-Specific Human T Lymphocyte Responses Including CD8+ Cytotoxic Activity after Receipt of Envelope Vaccines. The Journal of Infectious Diseases. 168(2). 306–313. 33 indexed citations
11.
Graham, Bria, Thomas J. Matthews, Robert B. Belshe, et al.. (1993). Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with gp160 in Vaccinia-Naive Adults. The Journal of Infectious Diseases. 167(3). 533–537. 127 indexed citations
12.
Belshe, Robert B., M L Clements, Raphael Dolin, et al.. (1993). Safety and Immunogenicity of a Fully Glycosylated Recombinant gp160 Human Immunodeficiency Virus Type 1 Vaccine in Subjects at Low Risk of Infection. The Journal of Infectious Diseases. 168(6). 1387–1395. 61 indexed citations
13.
Graham, Bria, Robert B. Belshe, M L Clements, et al.. (1992). Vaccination of Vaccinia-Naive Adults with Human Immunodeficiency Virus Type 1 gp160 Recombinant Vaccinia Virus in a Blinded, Controlled, Randomized Clinical Trial. The Journal of Infectious Diseases. 166(2). 244–252. 100 indexed citations
14.
Keefer, M. C., William Bonnez, Norbert J. Roberts, Raphael Dolin, & Richard C. Reichman. (1991). Human Immunodeficiency Virus (HIV-l) gp160-Specific Lymphocyte Proliferative Responses of Mononuclear Leukocytes from HIV-l Recombinant gp160 Vaccine Recipients. The Journal of Infectious Diseases. 163(3). 448–453. 38 indexed citations
15.
Keefer, M. C., et al.. (1991). Single-dose trospectomycin for chlamydial urethritis in men. Antimicrobial Agents and Chemotherapy. 35(5). 986–987. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary Clare Walker Breakdown of academic impact, for papers by Paul T. Edlefsen Breakdown of academic impact, for papers by Nina D. Russell Breakdown of academic impact, for papers by Dennis Ellenberger Breakdown of academic impact, for papers by Mary N. Phillips Breakdown of academic impact, for papers by Supachai Rerks‐Ngarm Breakdown of academic impact, for papers by Christine Hogan Breakdown of academic impact, for papers by William M. Hurni Breakdown of academic impact, for papers by R R Redfield Breakdown of academic impact, for papers by M J McElrath
Rankless by CCL
2026